Elevance Health’s (ELV) 2025 Guidance Reaffirmation Might Change the Case for Investing in ELV

• Elevance Health recently reaffirmed its 2025 earnings guidance and benefit expense ratio outlook at a series of investor meetings, including presentations by its CEO and CFO at industry conferences in early November 2025.
• This reiterated guidance provides investors with increased clarity on the company’s financial expectations amid ongoing competitive and regulatory headwinds in Medicaid and Medicare markets.
• We’ll examine how the company's emphasis on maintaining its benefit expense ratio may alter Elevance Health’s investment narrative and future outlook.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 37 best rare earth metal stocks of the very few that mine this essential strategic resource.

Elevance Health Investment Narrative Recap

To invest in Elevance Health, you must be confident in its ability to balance disciplined pricing, cost containment, and strategic use of technology to counter rising healthcare costs and regulatory complexity. The reaffirmed 2025 earnings and benefit expense ratio outlooks provide little change to the current short-term investment catalyst, margin stabilization via cost management, while the primary risk remains persistent medical cost inflation in government plans, which has not been materially reduced by this update.

Among recent announcements, Elevance’s ongoing dividends and substantial share buybacks attract attention, especially after it reaffirmed its long-term earnings targets. These shareholder returns reinforce management’s confidence and provide some stability despite current margin and cost headwinds highlighted in the latest earnings guidance.

But on the other hand, investors should not overlook how continued upward pressure on benefit costs could still...

Read the full narrative on Elevance Health (it's free!)

Elevance Health's outlook projects $230.4 billion in revenue and $7.4 billion in earnings by 2028. This requires 6.8% annual revenue growth and a $2.0 billion earnings increase from the current earnings of $5.4 billion.

Uncover how Elevance Health's forecasts yield a $389.16 fair value, a 28% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members have posted 16 fair value estimates for Elevance Health ranging from US$297 to US$1,082 per share. With cost trends still a central risk, your own outlook should weigh these differing views and the evolving impact on future margins.

Explore 16 other fair value estimates on Elevance Health - why the stock might be worth over 3x more than the current price!

Build Your Own Elevance Health Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Elevance Health research is our analysis highlighting 5 key rewards that could impact your investment decision.
• Our free Elevance Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Elevance Health's overall financial health at a glance.

Ready For A Different Approach?

Our top stock finds are flying under the radar-for now. Get in early:

• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com